Novartis Gets Positive Result From Breast-Cancer Drug Trial
27 March 2023 - 04:56PM
Dow Jones News
By Cecilia Butini
Novartis AG said Monday that a trial evaluating breast-cancer
drug Kisqali met its primary endpoint during an interim
analysis.
The drug is shown to significantly reduce the risk of disease
recurrence when used together with an endocrine therapy in patients
with certain types of early breast cancers at risk of recurrence,
the company said.
The Phase 3 trial, named Natalee, was stopped early as the
primary endpoint has been met, Novartis said.
Write to Cecilia Butini at cecilia.butini@wsj.com
(END) Dow Jones Newswires
March 27, 2023 01:41 ET (05:41 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
Novartis (NYSE:NVS)
Historical Stock Chart
From Feb 2024 to Mar 2024
Novartis (NYSE:NVS)
Historical Stock Chart
From Mar 2023 to Mar 2024